Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.62 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630241 | 1.00 | PREP (0.62) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL630208 | 1.00 | PREP (0.62) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29077433 | 0.99 | PREP (0.61) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7648948 | 0.99 | PREP (0.61) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7650461 | 0.99 | PREP (0.61) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7648946 | 0.99 | PREP (0.61) | PREPFKBP1ACTRB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29553 | 0.96 | PREP (0.67) | PREPCTRB1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL205223 | 0.96 | PREP (0.67) | PREPCTRB1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL29658848 | 0.96 | PREP (0.67) | PREPCTRB1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL475715 | 0.96 | PREP (0.67) | PREPCTRB1SMN1; SMN2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-114828959-A | 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE COMPANY (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2323972-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2010-07-01 | — | — | US | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | HCRTR2, HCRTR1, CNR1 | PREP 3970/4885FKBP1A 1060/4885CTRB1 782/4885 |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PREP 3423/4885FKBP1A 74/4885CTRB1 3877/4885 |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | PREP 3501/4885FKBP1A 3482/4885CTRB1 4846/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PREP 2440/4885FKBP1A 2759/4885CTRB1 3351/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | PREP 3584/4885FKBP1A 195/4885CTRB1 1806/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | PREP 168/4885FKBP1A 2366/4885CTRB1 3279/4885 |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | PREP 3584/4885FKBP1A 195/4885CTRB1 1806/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | PREP 3385/4885FKBP1A 3661/4885CTRB1 4841/4885 |
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | CCNI, NQO2, MKI67 | PREP 619/4885FKBP1A 709/4885CTRB1 3341/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | PREP 3584/4885FKBP1A 195/4885CTRB1 1806/4885 |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PREP 2440/4885FKBP1A 2759/4885CTRB1 3351/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | PREP 2440/4885FKBP1A 2759/4885CTRB1 3351/4885 |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | PREP 3584/4885FKBP1A 195/4885CTRB1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.